MX2016005166A - Derivados de tirosina y composiciones que los comprenden. - Google Patents

Derivados de tirosina y composiciones que los comprenden.

Info

Publication number
MX2016005166A
MX2016005166A MX2016005166A MX2016005166A MX2016005166A MX 2016005166 A MX2016005166 A MX 2016005166A MX 2016005166 A MX2016005166 A MX 2016005166A MX 2016005166 A MX2016005166 A MX 2016005166A MX 2016005166 A MX2016005166 A MX 2016005166A
Authority
MX
Mexico
Prior art keywords
particulate material
solid particulate
tyrosine derivative
compositions
tyrosine derivatives
Prior art date
Application number
MX2016005166A
Other languages
English (en)
Inventor
Hoffman Steven
Original Assignee
Tyme Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tyme Inc filed Critical Tyme Inc
Publication of MX2016005166A publication Critical patent/MX2016005166A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/40—Peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/02—Radiation therapy using microwaves
    • A61N5/022—Apparatus adapted for a specific treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/062—Photodynamic therapy, i.e. excitation of an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
    • A61N2005/0659—Radiation therapy using light characterised by the wavelength of light used infrared
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
    • A61N2005/0661—Radiation therapy using light characterised by the wavelength of light used ultraviolet
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
    • A61N2005/0662—Visible light
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092—Details
    • A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)
  • Materials For Medical Uses (AREA)

Abstract

Se proporcionan en la presente métodos que comprenden proporcionar un derivado de tirosina y un material de partículas sólidas (y, opcionalmente melanina) y aplicar fuerza a dicho derivado de tirosina y dicho material de partículas sólidas durante un tiempo y bajo condiciones efectivas para impregnar al menos uno de dicho derivado de tirosina y dicho material de partículas sólidas con el otro de dicho derivado de tirosina y dicho material de partículas sólidas. La invención proporciona también composiciones que comprenden al menos uno de un derivado de tirosina impregnado con un material de partículas sólidas y material de partículas sólidas impregnado con un derivado de tirosina.
MX2016005166A 2013-10-22 2014-10-21 Derivados de tirosina y composiciones que los comprenden. MX2016005166A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361894279P 2013-10-22 2013-10-22
US14/062,194 US9585841B2 (en) 2013-10-22 2013-10-24 Tyrosine derivatives and compositions comprising them
PCT/US2014/061527 WO2015061288A1 (en) 2013-10-22 2014-10-21 Tyrosine derivatives and compositions comprising them

Publications (1)

Publication Number Publication Date
MX2016005166A true MX2016005166A (es) 2016-12-14

Family

ID=52826750

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016005166A MX2016005166A (es) 2013-10-22 2014-10-21 Derivados de tirosina y composiciones que los comprenden.

Country Status (22)

Country Link
US (2) US9585841B2 (es)
EP (1) EP3060200B1 (es)
JP (1) JP6684210B2 (es)
KR (1) KR102292206B1 (es)
CN (1) CN106232105A (es)
AU (1) AU2014340263B2 (es)
CA (1) CA2927980C (es)
CY (1) CY1124386T1 (es)
DK (1) DK3060200T3 (es)
ES (1) ES2879947T3 (es)
HR (1) HRP20210999T1 (es)
HU (1) HUE055110T2 (es)
IL (1) IL245173B (es)
LT (1) LT3060200T (es)
MX (1) MX2016005166A (es)
PH (1) PH12016500729A1 (es)
PL (1) PL3060200T3 (es)
PT (1) PT3060200T (es)
RS (1) RS62216B1 (es)
SI (1) SI3060200T1 (es)
WO (1) WO2015061288A1 (es)
ZA (1) ZA201602770B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9585841B2 (en) * 2013-10-22 2017-03-07 Tyme, Inc. Tyrosine derivatives and compositions comprising them
US20170333451A1 (en) * 2016-05-18 2017-11-23 Tyme, Inc. Dihydrotestosterone and dihydrotestosterone derivatives and promoters in the treatment of cancer
MX2019005450A (es) * 2016-11-15 2019-07-04 Tyme Inc Composiciones y metodos farmaceuticos.
EP3548086A1 (en) 2016-11-30 2019-10-09 Tyme, Inc. Tyrosine derivatives and compositions comprising them
AU2018209164B2 (en) 2017-01-17 2021-11-04 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
CA3060417A1 (en) * 2017-04-21 2018-10-25 Steven Hoffman Compositions and methods for treating retinopathy
CN111032089A (zh) * 2017-07-19 2020-04-17 霍夫曼技术公司 用于治疗应激相关障碍的组合物
KR20190032250A (ko) * 2017-09-19 2019-03-27 주식회사 스킨큐씨 D-타이로신 또는 이를 포함하는 펩타이드를 포함하는 피부 미백용 조성물
RU2719575C1 (ru) * 2019-02-01 2020-04-21 Общество с ограниченной ответственностью "Центр ранней диагностики нейродегенеративных заболеваний (НДЗ)" Фармацевтическая композиция на основе альфа-метил-п-тирозина и способ ранней диагностики болезни Паркинсона
CA3140042A1 (en) * 2019-05-14 2020-11-19 Tyme, Inc. Compositions and methods for treating cancer
KR20220098144A (ko) * 2019-10-15 2022-07-11 타임, 인크. 암을 치료하는 데에 사용하기 위한 알파-메틸-dl-티로신의 알킬에스테르
JP2023511319A (ja) * 2020-01-17 2023-03-17 タイム，インコーポレーテッド がんを調節するための組成物および方法
US10905698B1 (en) 2020-05-14 2021-02-02 Tyme, Inc. Methods of treating SARS-COV-2 infections
WO2023128791A1 (ru) * 2021-12-30 2023-07-06 Общество С Ограниченной Ответственностью "Центр Ранней Диагностики Нейродегенеративных Заболеваний" Комбинированное лекарственное средство для ранней диагностики болезни паркинсона

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4189604A (en) 1975-07-22 1980-02-19 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Bestatin
CA1108180A (en) 1976-07-21 1981-09-01 Hamao Umezawa Analogs of bestatin
US4165382A (en) 1977-10-17 1979-08-21 Jose Pozuelo Method of pharmacologically treating schizophrenia with alpha-methyl-para-tyrosine
US4117161A (en) 1977-05-16 1978-09-26 Jose Pozuelo Method of pharmacologically treating drug addiction with alpha-methyl-para-tyrosine
US4389415A (en) 1978-01-24 1983-06-21 Merck & Co., Inc. Method of treating hypertension
US5206018A (en) 1978-11-03 1993-04-27 Ayerst, Mckenna & Harrison, Inc. Use of rapamycin in treatment of tumors
US5674839A (en) 1987-05-22 1997-10-07 Competitive Technologies, Inc. Cyclic analogs of alpha-MSH fragments
US5683981A (en) 1987-05-22 1997-11-04 Competitive Technologies, Inc. Cyclic bridged analogs of α-MSH and methods thereof
JP2668880B2 (ja) * 1987-06-23 1997-10-27 日本油脂株式会社 被覆アミノ酸類の製造方法
US4806360A (en) * 1987-10-23 1989-02-21 Advanced Polymer Systems Synthetic melanin aggregates
US5073541A (en) 1987-11-18 1991-12-17 Administrators Of The Tulane Educational Fund Treatment of small cell lung cancer with somatostatin analogs
JPH02286602A (ja) * 1989-04-28 1990-11-26 Nippon Tokushu Noyaku Seizo Kk 徐放性農薬粒剤
US5225435A (en) 1990-05-18 1993-07-06 Yale University Soluble melanin
US5310539A (en) * 1991-04-15 1994-05-10 Board Of Regents, The University Of Texas System Melanin-based agents for image enhancement
WO1994010968A1 (en) * 1992-11-19 1994-05-26 Bristol-Myers Squibb Company Compositions and methods for temporarily coloring hair using solubilized melanin
EP0687362A1 (en) * 1993-03-04 1995-12-20 Minister Of Agriculture Fisheries And Food In Her Britannic Majesty's Gov. Of The U.K. Of Great Britain And Northern Ireland Selective binding materials and assays
WO1994022460A1 (en) 1993-04-05 1994-10-13 University Patents, Inc. Diagnosis and treatment of erectile dysfunction
US8828432B2 (en) * 1996-10-28 2014-09-09 General Mills, Inc. Embedding and encapsulation of sensitive components into a matrix to obtain discrete controlled release particles
IT1291633B1 (it) 1997-04-22 1999-01-11 Pharmaconsult S A S Uso dell'alfa-metil-p-tirosina per inibire la produzione di melanina nei melanociti dell'iride
US20030059471A1 (en) 1997-12-15 2003-03-27 Compton Bruce Jon Oral delivery formulation
WO1999046283A1 (en) 1998-03-09 1999-09-16 Zealand Pharmaceuticals A/S Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
AU775289B2 (en) 1998-08-21 2004-07-29 Children's Medical Center Corporation Use of melanin for inhibition of angiogenesis and macular degeneration
CA2405549A1 (en) * 2000-04-03 2001-10-11 Hybridon, Inc. Sensitization of cells to cytotoxic agents using oligonucleotides directed to nucleotide excision repair or transcription coupled repair genes
US20030114362A1 (en) 2001-06-08 2003-06-19 Novaspin Biotech Gmbh Penta-or tetrapeptide binding to somatostatin receptors and the use of the same
US7482018B2 (en) * 2001-12-21 2009-01-27 Soane Family Trust Use of oligomers and polymers for drug solubilization, stabilization, and delivery
US8620406B2 (en) * 2004-01-23 2013-12-31 Boston Scientific Scimed, Inc. Medical devices visible by magnetic resonance imaging
WO2005072061A2 (en) * 2004-02-02 2005-08-11 Biosight Ltd. Conjugates for cancer therapy and diagnosis
AU2005326322B2 (en) * 2004-07-01 2009-02-05 Yale University Targeted and high density drug loaded polymeric materials
WO2006099288A2 (en) 2005-03-11 2006-09-21 Indevus Pharmaceuticals, Inc. Controlled release formulations of octreotide
ATE431140T1 (de) 2005-03-11 2009-05-15 Gpc Biotech Ag Antiproliferative kombinations-therapie mit satraplatin oder jm118 und docetaxel
AU2006231452B2 (en) * 2005-04-01 2011-05-26 Intezyne Technologies, Inc. Polymeric micelles for drug delivery
CN101516899B (zh) 2006-04-19 2016-07-06 得克萨斯大学体系董事会 细胞成像和治疗的组合物和方法
US8758723B2 (en) * 2006-04-19 2014-06-24 The Board Of Regents Of The University Of Texas System Compositions and methods for cellular imaging and therapy
US20090142337A1 (en) * 2006-05-08 2009-06-04 Astex Therapeutics Limited Pharmaceutical Combinations of Diazole Derivatives for Cancer Treatment
CN101138634A (zh) * 2006-09-07 2008-03-12 于保法 用于治疗肿瘤的组合物
FR2918990B1 (fr) * 2007-07-20 2012-12-21 Innov Ia Procede de preparation de compositions pulverulentes stables
WO2009054001A1 (en) 2007-10-22 2009-04-30 Biocon Limited A pharmaceutical composition and a process thereof
WO2009109649A1 (en) 2008-03-07 2009-09-11 Pharma Mar, S.A. Improved antitumoral treatments
EP2106806A1 (en) * 2008-03-31 2009-10-07 Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung e.V. Nanoparticles for targeted delivery of active agents to the lung
US20110098241A1 (en) 2008-04-14 2011-04-28 Poniard Pharmaceuticals, Inc. Rapamycin analogs as anti-cancer agents
KR101078302B1 (ko) * 2008-05-29 2011-10-31 (주)프로넥스 약물전달체
US20110200556A1 (en) 2008-08-20 2011-08-18 The United States Of America, As Represented By Th E Secretary, Department Of Health And Human Servi Chemoprevention of head and neck squamous cell carcinomas
US8110578B2 (en) 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
KR20130128018A (ko) 2009-04-10 2013-11-25 하이얀 치 새로운 노화 방지 물질 및 그 확인 방법
WO2011112576A1 (en) 2010-03-10 2011-09-15 Ambrilia Biopharma Inc. Microspheres for sustained release of octreotide acetate
WO2012012305A2 (en) * 2010-07-18 2012-01-26 Niiki Pharma Inc. Combination therapy using a ruthenium complex
DK2804599T3 (en) 2012-01-17 2019-02-04 Tyme Inc COMBINATION THERAPY FOR TREATMENT OF CANCER
US9724657B2 (en) * 2013-10-22 2017-08-08 Tyme, Inc. High-speed centrifugal mixing devices and methods of use
US9585841B2 (en) * 2013-10-22 2017-03-07 Tyme, Inc. Tyrosine derivatives and compositions comprising them

Also Published As

Publication number Publication date
JP2016534071A (ja) 2016-11-04
EP3060200A1 (en) 2016-08-31
PT3060200T (pt) 2021-07-07
PL3060200T3 (pl) 2021-10-11
LT3060200T (lt) 2021-08-25
AU2014340263A1 (en) 2016-05-19
ES2879947T3 (es) 2021-11-23
CA2927980A1 (en) 2015-04-30
DK3060200T3 (da) 2021-07-12
KR102292206B1 (ko) 2021-08-24
US9585841B2 (en) 2017-03-07
PH12016500729A1 (en) 2016-05-30
RS62216B1 (sr) 2021-09-30
JP6684210B2 (ja) 2020-04-22
US20170172924A1 (en) 2017-06-22
CA2927980C (en) 2022-07-19
KR20160072239A (ko) 2016-06-22
ZA201602770B (en) 2017-04-26
NZ719457A (en) 2021-02-26
US20150112116A1 (en) 2015-04-23
US11058638B2 (en) 2021-07-13
SI3060200T1 (sl) 2021-11-30
IL245173A0 (en) 2016-06-30
WO2015061288A1 (en) 2015-04-30
CN106232105A (zh) 2016-12-14
EP3060200B1 (en) 2021-05-26
HRP20210999T1 (hr) 2021-11-26
IL245173B (en) 2020-10-29
CY1124386T1 (el) 2022-07-22
HUE055110T2 (hu) 2021-10-28
AU2014340263B2 (en) 2019-11-21

Similar Documents

Publication Publication Date Title
PH12016500729A1 (en) Tyrosine derivatives and compositions comprising them
IL273752A (en) Ingredients, compounds and methods for increasing cftr activity
EP3676792A4 (en) DYNAMIC SCRIPTS FOR TELEAGENTS
MY193806A (en) Affinity-oligonucleotide conjugates and uses thereof
EP3341623A4 (en) OSCILLATING SKATE BEARING ASSEMBLIES, AND BEARING APPARATUSES AND METHODS FOR THEIR USE
EP3091870A4 (en) Porous pad for impregnation of liquid cosmetic composition and liquid-cosmetic-composition impregnating method using the same
EP3660040A3 (en) Insulin receptor partial agonists
IL261046A (en) Transduced 3,2,1-triazoles as selective nmda modulators for nr2b
CR20140529A (es) Anticuerpos e inmunoconjugados contra ly6e y métodos de uso
CL2016000685A1 (es) Material para protección balística, su método de preparación y uso.
EP3329383A4 (en) METHODS AND SYSTEMS FOR PRODUCING WYSIWYG WEB CONTENT
EP3082426A4 (en) Compounds, compositions and methods for attracting and/or arresting bed bugs
EP3225674A4 (en) Friction material composition, and friction material and friction member using said friction material composition
EP3299421A4 (en) Binder composition, and method for binding fibrous material by using same
EP3081380A4 (en) Inner-circulation high-speed hydraulic system, hydraulic platform, and hydraulic platform assembly
SG11201704321TA (en) Stable peptide-conjugated ascorbic acid derivative, method for preparing same, and cosmetic composition comprising same
EP3037431A4 (en) Vancomycin derivative, and preparation method and application thereof
WO2014091167A3 (fr) Composes cyclopropylboroniques, leur procede de preparation et leur utilisation
EP3133116A4 (en) Aqueous thermosetting binder composition and method for binding fibrous materials by using same
EP3239264A4 (en) Friction material composition, friction material using same, and friction member
EP3127956A4 (en) Aqueous binder composition and method for binding fibrous material using same
IL251456A0 (en) Substances with agonist activity for gpr119, processes for their preparation and preparations containing them
WO2014152809A3 (en) Analogs of pparo and 20-oh-pge2, and methods of using the same
EP3007256A4 (en) Electrode binder composition, and electrode
EP3254699A4 (en) Solid dispersion containing dutasteride, and composition containing same